Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

Michael Cecchini; Mario Sznol; Stuart Seropian

doi:10.1186/s40425-015-0054-4

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

J Immunother Cancer. 2015 Mar 24:3:10. doi: 10.1186/s40425-015-0054-4. eCollection 2015.

Authors

Michael Cecchini¹, Mario Sznol¹, Stuart Seropian¹

Affiliation

¹ Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA.

Abstract

Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.

Keywords: Allogeneic transplant; CTLA-4 antigen; Graft vs host disease; Immunotherapy; Interleukin-2; Ipilimumab; Melanoma; Programmed cell death 1 receptor and immune-related adverse events.